UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
eResearchTechnology, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
29481V 10 8
--------------------------------------------------------------------------------
(CUSIP Number)
October 28, 2003
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
--------------------------------------------------------------------------------
Schedule 13G Page 2 of 6
CUSIP NO. 29481V 10 8
--------------------------------------------------------------------------------
1. Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
Joel Morganroth, M.D. 362-44-6024
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
United States
--------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares 1,060,000
Beneficially
Owned by ----------------------------------------------------------
Each
Reporting 6. Shared Voting Power
Person With 28,800
----------------------------------------------------------
7. Sole Dispositive Power
1,060,000
----------------------------------------------------------
8. Shared Dispositive Power
28,800
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,988,800 (disclaims beneficial ownership of 928,800 shares)
--------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) |_|
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
8.8%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Schedule 13G Page 3 of 6
CUSIP NO. 29481V 10 8
--------------------------------------------------------------------------------
Item 1.
(a) Name of Issuer:
eResearchTechnology, Inc.
(b) Address of Issuer's Principal Executive Offices:
30 South 17th Street
Philadelphia, PA 19103
Item 2.
(a) Name of Person Filing:
Joel Morganroth, M.D.
(b) Address of Principal Business Office, if none, Residence:
30 South 17th Street
Philadelphia, PA 19103
(c) Citizenship:
United States
(d) Title of Class of Securities:
Common Stock, $.01 par value per share
(e) CUSIP Number:
29481V 10 8
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under Section 15 of
the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in Section 3(a)(6) of the
Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in Section 3(a)(19)
of the Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under Section 8 of
the Investment Company Act of 1940 (15 U.S.C.
80a-8).
(e) [ ] An investment adviser in accordance with ss.240.
13d-1(b)(1)(ii)(E).
(f) [ ] An employee benefit plan or endowment fund in
accordance with ss.240.13d-(b)(1)(ii)(F).
--------------------------------------------------------------------------------
Schedule 13G Page 4 of 6
CUSIP NO. 29481V 10 8
--------------------------------------------------------------------------------
(g) [ ] A parent holding company or control person
in accordance with ss.240.13d-1(b)(1)(ii)(G).
(h) [ ] A savings association as defined in Section
3(b) of the Federal Deposit Insurance Act
(12 U.S.C. 1813).
(i) [ ] A church plan that is excluded from the definition
of an investment company under Section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C.
80a-3).
(j) [ ] Group, in accordance with ss.240.13d-(b)(1)(ii)(J).
Not applicable.
Item 4. Ownership
(a) Amount beneficially owned:
1,988,800*
(b) Percent of Class:
8.8%*
(c) Number of Shares as to which the person has:
i. Sole power to vote or to direct the vote:
1,060,000*
ii. Shared power to vote or to direct the vote:
28,800*
iii. Sole power to dispose or to direct the
disposition of: 1,060,000*
iv. Shared power to dispose or to direct the
disposition of: 28,800*
________________
*850,000 shares are owned directly by Dr. Morganroth, as to which Dr. Morganroth
has sole voting and dispositive power. 28,800 shares are owned by a pension
plan, as to which Dr. Morganroth has shared voting and dispositive power.
900,000 shares are held in a trust, the trustee of which is Dr. Morganroth's
wife and the beneficiaries of which are Dr. Morganroth's children, and Dr.
Morganroth disclaims beneficial ownership of these shares. 210,000 shares are
underlying currently exercisable options granted under a stock option plan of
eResearchTechnology, Inc. All share amounts herein have been adjusted to reflect
the 2-for-1 stock split in the form of a 100% stock dividend to holders of
record on May 6, 2003, payable on May 29, 2003.
--------------------------------------------------------------------------------
Schedule 13G Page 5 of 6
CUSIP NO. 29481V 10 8
--------------------------------------------------------------------------------
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following. [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company or Control Person
Not applicable.
Item 8. Identification and Classification of Member of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
--------------------------------------------------------------------------------
Schedule 13G Page 6 of 6
CUSIP NO. 29481V 10 8
--------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: October 30, 2003 By: /s/ Joel Morganroth, M.D.
---------------- --------------------------
Joel Morganroth, M.D.